U.S. stocks are trading higher ahead of manufacturing data along with new home sales data which is expected tomorrow.
Keep Reading →
August 23 - Commodities, Market Movers, News, Tech - Comments
Insider Monkey follows around 730 of the best-performing money managers and even though many of them lost money in the last several months, the history shows that they still manage...
Keep Reading →
March 9 - Hedge Funds, News - Comments
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares reached as high as $83 per share in pre-market trading Monday, or over 18% higher than the stock’s closing price ...
Keep Reading →
July 27 - Hedge Funds, News - Comments
Conan Laughlin’s North Tide Capital posted impressive first quarter returns of 10.1% from its 14 long positions in companies valued at $1 billion or greater.
Keep Reading →
April 17 - Hedge Funds, News - Comments
Charter Oak Partners Management is a fundamentally driven Long/Short hedge fund that focuses mainly on equity investments. It was founded by Jerrold N.
Keep Reading →
March 26 - Hedge Funds, News - Comments
Chemical nerve agents have garnered much media coverage recently, but receiving less attention are the companies involved in the development of countermeasures to these and biological...
Keep Reading →
September 23 - News - Comments
Since 1983, Depakote ER has been a good source of revenue for drug manufacturers. The drug is mainly used in the treatment of bipolar disorder, migraines, and seizures.
Keep Reading →
September 13 - News - Comments
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
September 12 - News - Comments
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
September 10 - News - Comments
Orphan drug status, which is given to drugs meant for the treatment of rare diseases, offers drug developers a path to faster approval and enhanced market exclusivity.
Keep Reading →
September 6 - News - Comments
In the 21st century investor’s toolkit, there are dozens of methods shareholders can use to monitor their holdings.
Keep Reading →
August 27 - News - Comments
To many investors, hedge funds are assumed to be overrated, old financial vehicles of an era lost to time.
Keep Reading →
August 25 - News - Comments
Even with the broad-based S&P 500 retracing for three straight days amid worries that the Federal Reserve may begin paring back its monthly bond-buying program as early as next...
Keep Reading →
August 9 - News - Comments
It's finally Friday, and the S&P 500 is trying its hardest to find a reason to be happy.
Keep Reading →
August 3 - News - Comments
Insider Monkey tracks quarterly 13f filings from hundreds of hedge funds, including billionaire John Paulson’s Paulson & Co, and the firm's love of Bank of America Corp (NYSE...
Keep Reading →
July 31 - Hedge Funds - Comments
The company broke open a bombshell on Monday when it announced that it would break its business into three new divisions -- two focused around drugs, vaccines, and consumer products...
Keep Reading →
July 31 - News - Comments
The United States Court of Appeals is making this one miserable summer for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Keep Reading →
July 29 - News - Comments
Biotechnology medicine manipulates the genetic material of living organisms to produce pharmaceuticals, which in many instances are designed to combat diseases once considered...
Keep Reading →
July 25 - News - Comments
Last week's new corporate bond issues totaling nearly $17 billion marked four consecutive weeks below $20 billion.
Keep Reading →
June 27 - News - Comments
A new Supreme Court ruling presents pharmaceutical companies with a tough choice -- stop paying generic-drug producers to withhold generic options from the market, or risk getting...
Keep Reading →
June 20 - News - Comments
Nothing interests a value investor more than bad news. Where there's a lack of enthusiasm, there's usually a cheap stock. Hospira, Inc.
Keep Reading →
June 14 - News - Comments
Searching for potential stock investments can be a daunting task.
Keep Reading →
June 13 - Hedge Funds - Comments
Generic producers are often regarded as the safer players within BioPharma.
Keep Reading →
June 13 - News - Comments
Does the house of health care have a glass ceiling? For women looking to advance in the health care industry, that might appear to be the case. Consider that the U.S.
Keep Reading →
June 13 - News - Comments
Generic-drug makers have considerable tailwinds, making their outperformance in the past year unsurprising.
Keep Reading →
June 6 - News - Comments
Virtually every investor is quite familiar with the names of big pharmaceutical giants such as GlaxoSmithKline plc (ADR) (NYSE:GSK), Eli Lilly & Co.
Keep Reading →
May 30 - News - Comments
Recently, Actavis Inc (NYSE:ACT) announced that it would acquire Warner Chilcott Plc (NASDAQ:WCRX) for around $8.5 billion in total consideration.
Keep Reading →
May 30 - News - Comments
Mylan Inc. (NASDAQ:MYL) was in 27 hedge funds' portfolio at the end of March. MYL shareholders have witnessed a decrease in enthusiasm from smart money of late.
Keep Reading →
May 28 - News - Comments
Editor's Note: Related Tickers: Goldman Sachs Group, Inc. (NYSE:GS), Citigroup Inc. (NYSE:C), J.C. Penney Company, Inc. (NYSE:JCP), Herbalife Ltd.
Keep Reading →
May 17 - Hedge Funds - Comments
Paulson & Co., the hedge fund which notoriously nailed the popping of the housing bubble during the financial crisis (making its founder, John Paulson, a billionaire due to high...
Keep Reading →
May 16 - Hedge Funds - Comments
Actavis Inc (NYSE:ACT), the largest generic drug company in the US, just got even bigger.
Keep Reading →
May 1 - News - Comments
Last week we focused on five can't-miss earnings reports.
Keep Reading →
April 29 - News - Comments
Within the next few days, stocks for two orphan drugmakers could either soar or sink. Both Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and Raptor Pharmaceutical Corp.
Keep Reading →
April 24 - News - Comments
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), a pharmaceuticals company that makes money off of branded drugs as well as generics, is an interesting example of a company...
Keep Reading →
April 23 - News - Comments
Big pharma loves Obamacare, right? After all, the main lobbying group for big pharma, the Pharmaceutical Researchers and Manufacturers of America, or PhRMA, spent $150 million...
Keep Reading →
March 23 - News - Comments
U.S. generics firm Actavis Inc (NYSE:ACT), previously Watson Pharmaceuticals, reported a strong jump in its revenues in the fourth quarter and total earnings for 2012.
Keep Reading →
March 17 - News - Comments
Occasionally some of my friends ask me why I am hedged and market neutral in my investing. My answer is always the same.
Keep Reading →
February 22 - News - Comments
Here at The Motley Fool, we believe the best way to invest and maximize returns is by buying strong companies and owning them for a long time.
Keep Reading →
February 11 - News - Comments
Its narcolepsy drug Provigil saw generic competition from Par Pharmaceutical Companies, Inc. (NYSE:PRX) and Mylan Inc.
Keep Reading →
February 9 - News - Comments